MARKET

SNDX

SNDX

Syndax Pharmaceuticals Inc
NASDAQ
20.11
-0.59
-2.85%
After Hours: 20.11 0 0.00% 16:05 06/14 EDT
OPEN
20.52
PREV CLOSE
20.70
HIGH
20.55
LOW
19.98
VOLUME
783.09K
TURNOVER
0
52 WEEK HIGH
25.34
52 WEEK LOW
11.22
MARKET CAP
1.71B
P/E (TTM)
-6.2424
1D
5D
1M
3M
1Y
5Y
Syndax Reports Updated Positive Data From Phase 1/2 Combination Trials Of Revumenib
NASDAQ · 16h ago
Syndax Pharmaceuticals Discloses Updated Data From Multiple Combination Trials Of revumenib, The Company's Potent Small Molecule Menin Inhibitor, In Patients With Acute Leukemias
Revumenib has 96% CRc in one study of acute leukemia patients with mNPM1 or KMT2Ar AML. Data continue to support revumenib's potential to enhance current standard of care agents. The study was part of the BEAT AML trial.
Benzinga · 16h ago
SYNDAX PHARMACEUTICALS INC: 52% CRC (14 OF 27 PTS) OBSERVED IN AUGMENT-102 TRIAL
Reuters · 16h ago
Bank of America Securities Keeps Their Buy Rating on Syndax Pharmaceuticals (SNDX)
TipRanks · 1d ago
SYNDAX PHARMACEUTICALS INC <SNDX.O>: BOFA GLOBAL RESEARCH RAISES PRICE OBJECTIVE TO $31 FROM $29
Reuters · 1d ago
U.S. RESEARCH ROUNDUP-Avidity Biosciences, Broadcom, Cara Therapeutics
Wall Street analysts revise ratings and price targets on several U.S.-listed companies. Avidity Biosciences, Broadcom, Cara Therapeutics and 3M among companies. 3M raises to outperform from peer perform. Boeing, Amphenol and Boeing among companies with research actions on Thursday.
Reuters · 1d ago
PYXIS ONCOLOGY EXPANDS BOARD OF DIRECTORS WITH APPOINTMENT OF MICHAEL A. METZGER
Reuters · 4d ago
Weekly Report: what happened at SNDX last week (0603-0607)?
Weekly Report · 4d ago
More
About SNDX
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing pipeline of cancer therapies. Its product candidates include revumenib, and axatilimab. It is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant A. It is also exploring the use of revumenib as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.

Webull offers Syndax Pharmaceuticals Inc stock information, including NASDAQ: SNDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SNDX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SNDX stock methods without spending real money on the virtual paper trading platform.